Division of Cancer & Genetics, School of Medicine, Cardiff University, Wales, United Kingdom.
National Imaging Academy of Wales (NIAW), Pencoed, United Kingdom.
Br J Radiol. 2022 Oct 1;95(1139):20220437. doi: 10.1259/bjr.20220437.
CT and staging laparoscopy are routinely used to stage patients with gastric cancer, however the role of F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with CT (PET-CT) is uncertain. This systematic review synthesised the evidence regarding the impact of baseline PET-CT staging on treatment decisions and patient outcomes.
Systematic database searches were performed without date restriction. Studies reporting data in patients with gastric adenocarcinoma who underwent radiological staging were included. One reviewer screened titles and abstracts for suitability and two reviewers extracted data from included articles. Primary outcome was the reported change in management after PET-CT. Secondary outcomes were the rates of recurrence and overall survival between patients staged with and without PET-CT. Risk of bias was assessed using the ROBINS-I tool. PROSPERO registration (CRD42022304314).
Data from 11 studies recruiting 2101 patients between 2012 and 2021 were included. PET-CT was performed in 1422 patients. Change of management varied between 3% and 29% of cases. No studies compared recurrence or survival rates between patients staged with or without PET-CT. Adenocarcinoma of intestinal subtype tended to be more FDG-avid compared to diffuse or signet-ring subtypes. No randomised data existed, and studies were considered low quality with high risk of bias.
Evidence for the additional value of PET-CT in the gastric cancer staging pathway is limited. All studies reported a positive impact by preventing those with undetected metastatic disease on CT undergoing futile surgery. Future national guidelines should consider routine staging PET-CT in gastric cancer.
Studies indicated that FDG PET-CT added benefit in gastric cancer staging by detecting more distant metastases, but these studies were generally of low quality and at high risk of bias. Intestinal subtype of gastric adenocarcinoma tended to be more FDG-avid and therefore more distant metastases were subsequently detected.
CT 和分期腹腔镜检查通常用于对胃癌患者进行分期,然而 F-氟代脱氧葡萄糖(FDG)正电子发射断层扫描(PET)与 CT(PET-CT)联合的作用尚不确定。本系统评价综合了基线 PET-CT 分期对治疗决策和患者结局影响的证据。
系统地进行了数据库检索,不限制日期。纳入了报告接受放射学分期的胃腺癌患者数据的研究。一位评审员筛选标题和摘要以确定其适宜性,两位评审员从纳入的文章中提取数据。主要结局是 PET-CT 后报告的管理变化。次要结局是 PET-CT 分期患者与未行 PET-CT 分期患者的复发率和总生存率。使用 ROBINS-I 工具评估偏倚风险。PROSPERO 注册(CRD42022304314)。
纳入了 2012 年至 2021 年期间 11 项研究的 2101 例患者的数据。在 1422 例患者中进行了 PET-CT。管理变化在 3%至 29%的病例之间。没有研究比较了 PET-CT 分期患者与未行 PET-CT 分期患者的复发率或生存率。肠型腺癌比弥漫型或印戒细胞型更倾向于 FDG 摄取。没有随机数据,且研究质量较低,存在高偏倚风险。
在胃癌分期途径中,PET-CT 的额外价值的证据有限。所有研究均报告说,通过防止 CT 检测到的未检测到的转移性疾病的患者进行无效手术,从而产生了积极影响。未来的国家指南应考虑在胃癌中常规进行分期 PET-CT。
研究表明,FDG PET-CT 通过检测更多远处转移,在胃癌分期中增加了益处,但这些研究普遍质量较低,存在高偏倚风险。胃腺癌的肠型倾向于更强烈地摄取 FDG,因此随后检测到更多远处转移。